Clinical trials: Tumor Gastric
Gastric Cancer (GC), Colorectal Cancer
Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer
The goal of this observational study is to learn whether a computer program can suggest cancer treatments that match expert recommendations for people with gastrointestinal cancer (cancer of the pancreas, stomach, or colon and…
- Conditions
- Gastric Cancer (GC), Colorectal Cancer, Pancreatic Cancer
- Trial name
- KITuKo (NCT07592338)
- Testing
- Treatment recommendation according to official German cancer guideline, Treatment recommendation of a LLM, Treatment recommendation of a multidisciplinary tumor board
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Gastric or Esophagogastric Junction Adenocarcinoma
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy)…
- Trial name
- NCT05180734
- Where
- 71 sites in China
- Volunteers
- 878 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Gastric Cancer
Effect of Pneumoperitoneum on the Continuous and Non-invasive Hemoglobin Monitoring
The primary purpose of this study is to investigate the effect of pneumoperitoneum on the continuous and non-invasive hemoglobin monitoring during laparoscopic gastrectomy
- Trial name
- NCT03430778
- Testing
- High end-tidal CO2, Low CO2 group
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Ajou University School of Medicine
Gastric Cancer
Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
Mediastinal lymph node dissection has been adopted as standard treatment for adenocarcinoma of esophagogastric junction(AEJ). This multi-center, exploratory, prospective, cohort study aims at provide standard technical details of…
- Trial name
- NCT04443478
- Testing
- Radical gastrectomy with dissection of lower mediastinal lymph node
- Where
- China
- Volunteers
- 1,036 people
- Sponsor
- Peking University
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Stomach Neoplasms, Robotic Surgical Procedures
Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
To evaluate the safety and efficacy of SP1000 and conventional laparoscopy in radical gastrectomy for proximal gastric cancer.
- Trial name
- NCT07586384
- Testing
- Single-Port Robotic Surgical System, Traditional Laparoscopic Surgery
- Where
- China
- Volunteers
- 90 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Gastric Cancer (GC)
Recurrence and Prognosis Prediction Model for Gastric Cancer
This study, utilizing a large-scale multicenter Eastern database, has established a Deep Learning-based predictive model for recurrence following gastric cancer surgery, which demonstrates robust discriminatory power for early…
- Trial name
- NCT07243847
- Testing
- surgery and/or chemo
- Volunteers
- 5,000 people
- Sponsor
- Fudan University
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT05583149
- Testing
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Patrick C. Johnson, MD
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Low Grade Intraepithelial Neoplasia, High Grade Intraepithelial Neoplasia
Comparison of pCLE and EB in Gastric Lesion Diagnosis
This is a prospective multicenter comparative study, aiming to compare probe-based confocal laser endomicroscopy (pCLE) and endoscopic biopsies in the diagnosis of the whole specific gastric lesion especially for distinguishing…
- Conditions
- Low Grade Intraepithelial Neoplasia, High Grade Intraepithelial Neoplasia, Early Gastric Cancer, Gastric Intraepithelial Neoplasia
- Trial name
- NCT06389448
- Testing
- pCLE-gastr
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Huazhong University of Science and Technology
Neoplasms Pancreatic
ImmunoPET Imaging of Pancreatic Cancer
Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a wide range of cancers, including pancreatic cancer.
- Trial name
- NCT06602037
- Testing
- [89Zr]Zr-DFO-SHR1920, [18F]F-RESCA-3A12, [68Ga]Ga-NOTA-3A12
- Where
- China
- Volunteers
- 90 people
- Sponsor
- RenJi Hospital
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast…
- Conditions
- Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer
- Trial name
- NCT06384417
- Testing
- Hello for Cancer game, Table Topics game
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Milton S. Hershey Medical Center
STOMACH NEOPLASM
Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting
The therapeutic regimens for adjuvant and neoadjuvant chemotherapy in gastric cancer (GC) predominantly hinge on clinical experience.
- Trial name
- NCT06792149
- Testing
- surgical resection, Adjuvant chemotherapy, neoadjuvant therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Early Gastric Cancer, Tumor Organoids
A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients
Early gastric cancer（AGC）has no effective characteristic symptoms and signs according to clinical statistics. Neoadjuvant chemotherapy (NAC) significantly reduces the size of AGC tumors so that it has become the recommended…
- Trial name
- NCT05442138
- Volunteers
- 54 people
- Sponsor
- Henan Cancer Hospital
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Gastric Cancer
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with…
- Trial name
- EXPAND (NCT00678535)
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- 130 sites in Argentina, Australia and 23 more
- Volunteers
- 904 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.